| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.41 | 2e-16 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.29 | 1e-13 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.25 | 1e-11 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.22 | 8e-11 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.26 | 5e-10 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-09 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-09 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.24 | 9e-09 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-08 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |